Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$3.89M-42.9%
XER
Xeris Biopharma Holdings, Inc.XERS
$889K+5.3%
Opko Health logo
Opko HealthOPK
$137K-68.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$454K+4.8%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%
Enterprise value$1.87B+5.8%
P/E20.4×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's debt issuance cost amortization?
ANI Pharmaceuticals (ANIP) reported debt issuance cost amortization of $358K in Q1 2026.
How has ANI Pharmaceuticals's debt issuance cost amortization changed year-over-year?
ANI Pharmaceuticals's debt issuance cost amortization increased by 10.5% year-over-year, from $324K to $358K.
What is the long-term trend for ANI Pharmaceuticals's debt issuance cost amortization?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's debt issuance cost amortization has grown at a -14.3% compound annual growth rate (CAGR), from $2.51M to $1.36M.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).